期刊文献+

清肾方联合西药治疗活动期狼疮性肾炎的研究 被引量:2

Study on the effect of Qingshen decoction combined with western medicine on active lupus nephritis
下载PDF
导出
摘要 目的观察清肾方联合西药治疗活动期狼疮性肾炎的临床疗效。方法将60例活动期狼疮性肾炎患者随机分为2组,对照组30例采用波尼松+环磷酰胺治疗,治疗组在对照组治疗基础上给予清肾方加减治疗。观察2组临床疗效,比较治疗前后SLE疾病活动指数(SLEDAI)积分、中医证候积分量化表(SLEFI)评分及实验室检查指标[血沉、24 h尿蛋白、血清白蛋白(ALB)、尿红细胞、补体C3、补体C4、血清Ig G、C反应蛋白(CRP)、人高迁移率族蛋白B1(HMGB1)、白细胞介素(IL)-17及抗核抗体(ANA)、抗双链DNA抗体(ds-DNA)阳性率]的差异。结果治疗组临床总有效率明显高于对照组(P<0.05)。治疗后2组SLEDAI积分、SLEFI评分及实验室各检查指标均较治疗前明显改善(P均<0.05),且除尿红细胞、ANA及ds-DNA阳性率外其余指标治疗组改善情况均明显优于对照组(P均<0.05)。治疗组不良反应发生率明显低于对照组(P<0.05)。结论清肾方联合西药治疗活动期狼疮性肾炎能明显改善患者临床症状及相关实验室指标,提高临床疗效,且安全性好。 Objective It is to observe the clinical efficacy of Qingshen prescription combined with western medicine on active lupus nephritis. Methods 60 patients with active lupus nephritis were randomly divided into two groups,the control group of 30 patients were treated with pure western medicine treatment( prednison + cyclophosphamide),the treatment group were treated with Qingshen prescription additionally on the basis of treatment in control group. The clinical curative effect,changes of SLEDAI scores,SLEFI scores,and laboratory physical and chemical indicators such as ESR,24 hour proteinuria,serum ALB,urine RBC,C3,C4,serum Iga G,CRP,HMGB1,IL-17 and ANA,ds-DNA positive rate before and after treatment were observed. Results The clinical total effective rate in treatment group was higher than that in control group( P〈 0. 05).After treatment,SLEDAI scores,SLEFI scores and laboratory physical and chemical indicators in both groups were improved significantly( P all 〈0. 05),the improvements of all the indicators except urine RBC,ANA and ds-DNA positive rate in treatment group were better than those in control group( P all 〈0. 05). The occurrence rate of side effect in treatment group was lower than that in control group( P〈 0. 05). Conclusion Qingshen prescription combined with western medicine can significantly improve the lupus nephritis patients' clinical symptoms,laboratory indexes and the clinical curative effect with good safety and feasibility.
出处 《现代中西医结合杂志》 CAS 2015年第35期3890-3892,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 狼疮性肾炎 清肾方 人高迁移率族蛋白B1 白细胞介素-17 lupus nephritis Qingshen prescription HMGB1 IL-17
  • 相关文献

参考文献10

二级参考文献76

  • 1刘冠贤,邓安国,方敬爱,刘建社,王玉梅,石咏军.狼疮肾炎患者尿单核细胞趋化蛋白-1检测的临床意义[J].中华风湿病学杂志,2005,9(10):618-619. 被引量:5
  • 2董月青,姚咏明,刘辉,董宁,于燕,盛志勇.烫伤后高迁移率族蛋白B1的变化及其对脾淋巴细胞周期的影响[J].解放军医学杂志,2005,30(10):861-863. 被引量:3
  • 3Wang Y,Hu Q,Madri JA,et al.Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5[J].Proc Natl Acad Sci USA,1996,93(16):8563-8568. 被引量:1
  • 4Uhm WS,Na K,Song GW,et a1.Cytokines balance in kidney tissues from lupus nephritis patients[J].Rheumatology (Oxford),2003,42(8):935-938. 被引量:1
  • 5Shimohata H,Yamada A,Yoh K,et al.Overexpression of T-bet in T cells accelerates autoimmune glomerulonephritis in mice with a dominant Th1 background[J].J Nephrol,2009,22(1):123-129. 被引量:1
  • 6Tucci M,Quatraro C,Lombardi L,et al.Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis:role of interleukin-18[J].Arthritis Rheum,2008,58(1):251-262. 被引量:1
  • 7Li HH,Cheng HH,Sun KH,et al.Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis[J].Clin Immunol,2008,129(2):277-285. 被引量:1
  • 8Matsumura R,Umemiya K,Sugiyama T,et al.Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis:a prospective series of nine patients[J].Clin Exp Rheumatol,2009,27(3):416-421. 被引量:1
  • 9Principi M,Di Leo A,Ingrosso M,et al.Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease:a case report[J].Immunopharmacol Immunotoxicol,2004,26(2):243-248. 被引量:1
  • 10Charles PJ,Smeenk RJ,De Jong J,et al.Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab,a monoclonal antibody to tumor necrosis factor alpha:findings in open-label and randomized placebo-controlled trials[J].Arthritis Rheum,2000,43(11):2383-2390. 被引量:1

共引文献166

同被引文献23

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部